![What's in a Suffix? FDA's Dilemma: How to Name Biologics](https://cdn.cancerletter.com/media/2015/09/24001012/41-33-cola-beer-juice-biosimilar-cancer-drug.jpg)
![What's in a Suffix? FDA's Dilemma: How to Name Biologics](https://cdn.cancerletter.com/media/2015/09/24001012/41-33-cola-beer-juice-biosimilar-cancer-drug.jpg)
Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- “All in Her Head” catalogs the history of medicine’s atrocities against women
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - Chernobyl: a 35 year follow up on long-term health effects
- Suspensions, public outrage ensue as tensions over Middle East sweep through oncology
NYU Cancer Center Director Benjamin Neel suspended over social media posts - What are you reading in 2024?
- Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored
Three reprimands later, he retains leadership—and mentorship—positions